A Phase 3 Study of MP-424 in Combination With IFN Beta and RBV, in Subjects With Genotype 1/2 Hepatitis C, Who Are Treatment-Naive or Have Received Interferon Based Therapy

Trial Profile

A Phase 3 Study of MP-424 in Combination With IFN Beta and RBV, in Subjects With Genotype 1/2 Hepatitis C, Who Are Treatment-Naive or Have Received Interferon Based Therapy

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Oct 2015

At a glance

  • Drugs Telaprevir (Primary) ; Interferon beta; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Mitsubishi Tanabe Pharma Corporation
  • Most Recent Events

    • 23 Oct 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 09 Jun 2015 Planned End Date changed from 1 May 2015 to 1 Nov 2015 as reported by ClinicalTrials.gov
    • 09 Jun 2015 Planned primary completion date changed from 1 May 2015 to 1 Nov 2015 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top